{"result": "(\"entity\"<|>GRP<|>ORGANIZATION<|>GRP is a medical device or procedure related to nutritional support for patients, particularly in oncology.)\n##\n(\"entity\"<|>CCEE<|>ORGANIZATION<|>CCEE refers to a clinical center or institution involved in the evaluation and treatment of patients.)\n##\n(\"entity\"<|>SNO<|>ORGANIZATION<|>SNO refers to specific nutritional supplements or formulas prescribed for patients with dietary needs.)\n##\n(\"entity\"<|>DM<|>ORGANIZATION<|>DM refers to diabetes management, which involves dietary and medical interventions for patients with diabetes.)\n##\n(\"entity\"<|>A1c<|>EVENT<|>A1c is a blood test that measures average blood glucose levels over the past 2 to 3 months, important for diabetes management.)\n##\n(\"entity\"<|>NE<|>ORGANIZATION<|>NE refers to nutritional enteral support, a method of providing nutrition to patients who cannot eat by mouth.)\n##\n(\"entity\"<|>PATIENT<|>PERSON<|>The patient is an individual undergoing treatment for head and neck neoplasia, requiring nutritional support and monitoring.)\n##\n(\"entity\"<|>NEOPLASIA<|>EVENT<|>Neoplasia refers to the presence of a tumor or abnormal growth of tissue, which can affect nutritional status and treatment approaches.)\n##\n(\"relationship\"<|>PATIENT<|>CCEE<|>The patient is being evaluated and treated at CCEE for their nutritional needs and medical condition<|>8)\n##\n(\"relationship\"<|>PATIENT<|>GRP<|>The patient was using the GRP for nutritional support during their treatment<|>7)\n##\n(\"relationship\"<|>PATIENT<|>SNO<|>The patient was prescribed SNO to meet their nutritional requirements<|>7)\n##\n(\"relationship\"<|>PATIENT<|>DM<|>The patient is being managed for diabetes, which affects their nutritional treatment<|>6)\n##\n(\"relationship\"<|>PATIENT<|>NE<|>The patient is receiving NE due to their inability to maintain adequate oral intake<|>8)\n##\n(\"relationship\"<|>PATIENT<|>A1c<|>The patient's A1c levels are monitored to assess their diabetes management<|>5)\n##\n(\"relationship\"<|>NEOPLASIA<|>PATIENT<|>The patient has neoplasia, which impacts their nutritional needs and treatment plan<|>9)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ógico. Plantea-\nban retirar sonda GRP en próxima visita, por lo que en CCEE de UN se decidió mantener\nla misma pauta de NE y de insulina, se solicitó recambio de sonda GRP y se citó en 3\nmeses para valorar retirada definitiva de GRP.\n\n\n\n                                                                                                              141\n---\n              En la figura 1 se puede ver una gráfica de la evolución de los pesos desde el\n     momento de la primera valoración hasta esta visita.\n\n\n\n     Figura 1. Evolución del peso (kg) a lo largo de la evolución del paciente\n\n\n\n              En su siguiente revisión, el paciente había recuperado la ingesta oral, sin\n     emplear la NE por la GRP. Presentaba muy buen estado general, llevando una vida más\n     activa incluso practicando deporte. Había desaparecido el edema en la laringe, pero\n     había perdido peso, 5 kg, pesando 66,3 kg. Las glucemias seguían estables con el mismo\n     tratamiento y ajustando la insulina, con una A1c de 7,2%. Con todo esto, se retiró defini-\n     tivamente la sonda GRP y se pautaron 2 SNO específicos para DM, para tomar separados\n     de las comidas principales, además de optimizarse la dosis de insulina.\n\n\n\n              En su última cita en CCEE se ha confirmado la buena evolución clínica del pa-\n     ciente, con plena ingesta oral, y aumentando 2 kg de peso, sin necesidad de tomar SNO\n     y con una vida completamente activa. De momento, no hay signos locales ni regionales\n     de recidiva tumoral.\n\n\n\n     Discusión\n              Como hemos citado, la patología oncológica en general y la de cabeza y cue-\n     llo entrañan independientemente del estado nutricional previo, un riesgo nutricional6 .\n     Concretamente, las neoplasias ORL por lo que pueden afectar a la vía oral, requieren\n     de un abordaje nutricional especial de forma profiláctica a cualquier medida terapéu-\n     tica, ya sea quirúrgica, QT o RT. Este abordaje lo comprende la decisión de poner una\n     ostomía (gastro o yeyunostomía), ya sea radiológica, endoscópica o quirúrgica, previo\n     al tratamiento, en vistas a prevenir la adecuada ingesta oral/enteral posteriores. No\n     hay predilección por el tipo o la vía de aplicación de dicho estoma en cuanto a manejo\n     o complicaciones, hay que individualizar en función del perfil del paciente7 .\n              Aunque no hay una evidencia fuerte en los estudios disponibles de que se deba\n     aplicar profilácticamente, se acepta que la gastrostomía/yeyunustomía profiláctica\n\n\n\n142\n---\ncomparado con la puesta a demanda o la ingesta oral exclusivamente sin aplicar osto-\nmías, mejora el estado nutricional, reduciendo la pérdida de peso, además de ser bene-\nficioso clínica, económicamente y en cuanto a la calidad de vida del paciente. Con todo\nesto, las principales guías de práctica clínica abogan por individualizar en la medida de\nlo posible, en función de la localización y afectación tumoral, el impacto nutricional de\nlos tratamientos que se le van a aplicar, la presencia de disfagia o afagia y la morbili-\ndad asociada al tipo y técnica de la colocación de la ostomía2 .\n         Las principales guías del abordaje nutricional en el paciente con neoplasia de\ncabeza y cuello se decantan en que se debe tratar al paciente con NE si se prevé que la\ningesta oral va a ser inferior al 60% en los próximos 10 días, sin predilección por el tipo\nde fórmula, siendo las fórmulas estándar y poliméricas las más aceptadas. Si se prevé\nque esta NE va a durar más de 4 semanas se debe indicar la gastrostomía2 .\n         Un especial interés en las neoplasias de ORL lo abarca las fórmulas inmu-\nnomoduladoras: fórmulas de NE o SNO que contienen aminoácidos, nucleótidos,\nácidos grasos omega 3, arginina y glutamina. En algunos estudios, han demostrado\nque en cabeza y cuello pueden mejorar el estado nutricional y sobretodo disminuir\nlas complicaciones postquirúrgicas de la herida como la infección o dehiscencia de\nsutura, así como la estancia hospitalaria8 . De hecho, la guía ESPEN de Nutrición en\nel Paciente Oncológico, incluye las neoplasias de cabeza y cuello dentro de las que\nse benefician de las fórmulas inmunomoduladoras, previo y posterior a la interven-\nción quirúrgica independientemente de su estado nutricional6 . Específicamente en\ncabeza y cuello, la arg\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}